100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
Leerboek oncologieverpleegkunde samenvatting $23.30   Add to cart
Quickly navigate to
Preview
  2.  
  3. Haagse Hogeschool (HHS)
  4.  
  5. Minor oncologie (GVSHMVT21ONCO)

Summary

Leerboek oncologieverpleegkunde samenvatting

 12 views  0 purchase
  • Course
  • Minor oncologie (GVSHMVT21ONCO)
  • Institution
  • Haagse Hogeschool (HHS)
  • Book
  • Leerboek oncologieverpleegkunde

Samenvatting leerboek oncologieverpleegkunde. Voor de minor Oncologie aan de Haagse hogeschool voor de Basiskennistoets. Deze toets komt ieder semester terug. Boek is 100 euro nieuw. In deze samenvatting staat alles voor het behalen van een 10 voor de Basiskennistoets van de minor.

Preview 4 out of 153  pages

Document information

  • No
  • Hoofdstuk 1, 8, 14, 16, 19, 20, 21, 24, 25, 26, 27
  • June 20, 2024
  • 153
  • 2023/2024
  • Summary

Subjects

  • gynaecologie
  • bassiskennistoets
  • oncologie
  • minor
  • samenvatting leerboek oncologieverpleegkunde
  • darm borst huid long hersenen prostaat
  • hhs

Connected book

book image

Book Title:

Author(s):

  • Edition:
  • ISBN:
  • Edition:

Written for

  • Haagse Hogeschool (HHS)
  • Verpleegkunde / HBO V
  • Minor oncologie (GVSHMVT21ONCO)
All documents for this subject (6)

Seller

avatar-seller
JoosjeHBOV

Content preview

Samenvatting minor oncologie verpleegkunde 2024

,Darmkanker .................................................................................................................................................. 11
Anatomie en fysiologie ..................................................................................................................................... 11
Problemen met de darmen ............................................................................................................................... 12
Etiologie en epidemiologie ............................................................................................................................... 12
Preventie........................................................................................................................................................... 13
Symptomatologie ............................................................................................................................................. 14
Diagnostiek ....................................................................................................................................................... 14
Pathologie ........................................................................................................................................................ 15
Behandeling ...................................................................................................................................................... 16
Chirurgie ...................................................................................................................................................... 16
Postoperatieve zorg ..................................................................................................................................... 18
Adjuvante behandelingen............................................................................................................................ 19
Palliatieve zorg............................................................................................................................................. 20
Follow-up ..................................................................................................................................................... 20
Rectumcarcinoom ............................................................................................................................................. 21
Preventie ..................................................................................................................................................... 21
Symptomatologie ........................................................................................................................................ 21
Diagnostiek .................................................................................................................................................. 21
Behandeling ................................................................................................................................................. 22
Chirurgie ...................................................................................................................................................... 22
Postoperatieve complicaties ....................................................................................................................... 23
Palliatieve zorg............................................................................................................................................. 24
Prognose en follow up ................................................................................................................................. 24
Stoma-, wond en incontinentiezorg.................................................................................................................. 24
Urinestoma .................................................................................................................................................. 24
Stomaproblemen ......................................................................................................................................... 24

Mammacarcinoom........................................................................................................................................ 26
Anatomie en fysiologie ..................................................................................................................................... 26
Etiologie en epidemiologie ............................................................................................................................... 27
Preventie........................................................................................................................................................... 28
Vroegtijdige screening ................................................................................................................................. 28
Risicofactoren .............................................................................................................................................. 29
Symptomatologie ............................................................................................................................................. 30
Diagnostiek ....................................................................................................................................................... 30
Anamnese en lichamelijk onderzoek ........................................................................................................... 31
Radiologisch onderzoek ............................................................................................................................... 32
Pathologie ........................................................................................................................................................ 33
Soorten borstkanker .................................................................................................................................... 34
Ductaal carcinoma in situ (DCIS) ............................................................................................................. 34
Lobulair carcinoma in situ (LCIS) ............................................................................................................. 34
Invasief carcinoom NST. .......................................................................................................................... 34
Invasief lobulair carcinoom. .................................................................................................................... 34
Hormoongevoelige borstkanker. ............................................................................................................ 35
HER2-positieve borstkanker.................................................................................................................... 35
Triple negatieve borstkanker. ................................................................................................................. 35
Inflammatoire borstkanker. .................................................................................................................... 35

, Carcinoom in situ ......................................................................................................................................... 35
Lokaal uitgebreid mammacarcinoom .......................................................................................................... 35
Stadium IIB-ziekte: .................................................................................................................................. 35
Stadium IIIA-ziekte: ................................................................................................................................. 36
Stadium IIIB-ziekte: ................................................................................................................................. 36
Stadium IIIC-ziekte: ................................................................................................................................. 36
Behandeling ...................................................................................................................................................... 37
Lokale en locoregionale behandeling .......................................................................................................... 37
Mammasparende therapie = MST .......................................................................................................... 37
Gemodificeerde radicale mastectomie = GRM ....................................................................................... 38
Lumpectomie .......................................................................................................................................... 38
Oncoplastische mammachirurgie ........................................................................................................... 38
Mastectomie ........................................................................................................................................... 38
Chirurgie van de oksel ............................................................................................................................. 38
Radiotherapie .............................................................................................................................................. 39
(Neo)-Adjuvante systeemtherapie .......................................................................................................... 40
Neo-adjuvante systeemtherapie ............................................................................................................ 40
Adjuvante systeemtherapie .................................................................................................................... 41
Mamareconstructie .......................................................................................................................................... 41
Technieken .................................................................................................................................................. 41
Prothese .................................................................................................................................................. 41
Reconstructie met eigen weefsel ................................................................................................................ 41
Weefselverplaatsing ............................................................................................................................... 41
DIEP-LAP.................................................................................................................................................. 41
S-GAP ...................................................................................................................................................... 42
Overige reconstructie methoden ............................................................................................................ 42
Reconstructie tepel en tepelhof ............................................................................................................. 42
Behandeling gemetastaseerde ziekte ............................................................................................................... 42
Systeemtherapie .......................................................................................................................................... 42
- Anti-hormonale therapie ............................................................................................................... 42
- Hormoontherapie .......................................................................................................................... 42
- Palliatieve chemotherapie ............................................................................................................. 43
- Immunotherapie ........................................................................................................................... 43
- Targeted therapie .......................................................................................................................... 43
- Toediening van bisfosnaten .......................................................................................................... 43
Palliatieve radiotherapie ......................................................................................................................... 44
Prognose en follow up ...................................................................................................................................... 44
Follow-up ..................................................................................................................................................... 45
Specifieke zorg problematiek en mogelijke interventies................................................................................... 45
Complicaties ................................................................................................................................................ 45
Bijwerkingen van chemotherapie: .......................................................................................................... 46
Lymfoedeem ........................................................................................................................................... 46
Lichamelijke en psychosociale problemen: ............................................................................................ 47

Dermatologische oncologie ........................................................................................................................... 48
Anatomie en fysiologie ..................................................................................................................................... 48
Etiologie en epidemiologie ............................................................................................................................... 49
Preventie........................................................................................................................................................... 50
Primaire preventie ....................................................................................................................................... 50
Secundaire preventie ................................................................................................................................... 51
Tertiaire Preventie ....................................................................................................................................... 51
Symptomatologie ............................................................................................................................................. 51

, Anamnese .................................................................................................................................................... 51
Lichamelijk onderzoek ................................................................................................................................. 52
ABCDE regel: ........................................................................................................................................... 52
Basaalcelcarcinoom .......................................................................................................................................... 53
Etiologie en epidemiologie .......................................................................................................................... 53
Etiologie .................................................................................................................................................. 53
Vormen ................................................................................................................................................... 53
Symptomatologie ........................................................................................................................................ 53
Diagnostiek en stadiëring ............................................................................................................................ 53
Behandeling ................................................................................................................................................. 54
1. Chirurgie ........................................................................................................................................ 54
2. Mohs micrografische chirurgie (MMC).......................................................................................... 54
3. Cryotherapie .................................................................................................................................. 54
4. Lokale therapie met cytostatische (5-FU) of immuunmodulerende (imiquimod) cremes ............ 55
5. Fotodynamische therapie .............................................................................................................. 55
6. Radiotherapie ................................................................................................................................ 55
7. Doelgerichte therapie.................................................................................................................... 55
Prognose en follow-up................................................................................................................................. 55
Plaveiselcelcarcinoom....................................................................................................................................... 56
Etiologie en epidemiologie .......................................................................................................................... 56
Risicofactoren .............................................................................................................................................. 56
Symptomatologie ........................................................................................................................................ 56
Diagnostiek en stadiëring ............................................................................................................................ 57
Behandeling ................................................................................................................................................. 57
1. Chirurgie ........................................................................................................................................ 57
2. Radiotherapie ................................................................................................................................ 58
3. Immuuntherapie ........................................................................................................................... 58
4. Overige .......................................................................................................................................... 58
Prognose en follow up ................................................................................................................................. 58
Prognose ................................................................................................................................................. 58
Follow-up ................................................................................................................................................ 58
Melanoom ........................................................................................................................................................ 59
Epidemiologie en etiologie .......................................................................................................................... 59
Risicofactoren .............................................................................................................................................. 59
Endogeen ................................................................................................................................................ 59
Exogeen................................................................................................................................................... 59
Metastasen ............................................................................................................................................. 59
Diagnostiek en stadiëring ............................................................................................................................ 60
Histologisch onderzoek................................................................................................................................ 61
Pathologisch onderzoek: ............................................................................................................................. 61
Behandeling ................................................................................................................................................. 61
Stadium I&II ............................................................................................................................................ 61
Bij stadium III .......................................................................................................................................... 62
Systemische behandeling........................................................................................................................ 64
Schildwachtklierprocedure ..................................................................................................................... 64
Follow-up en prognose ................................................................................................................................ 64
Merkelcelcarcinoom ......................................................................................................................................... 66
Epidemiologie en etiologie .......................................................................................................................... 66
Symptomatologie ........................................................................................................................................ 66
Behandeling ................................................................................................................................................. 66
Prognose en follow up ................................................................................................................................. 66
Symptomatologie ............................................................................................................................................. 67
Diagnostiek ....................................................................................................................................................... 67

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller JoosjeHBOV. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $23.30. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

77858 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$23.30
  • (0)
  Add to cart